New cocktail of drugs takes on tough pancreatic cancer
NCT ID NCT07488884
First seen Apr 05, 2026 · Last updated Jun 22, 2026 · Updated 12 times
Summary
This early-phase trial tests whether adding three experimental drugs (nogapendekin alfa inbakicept, sotevtamab, and zabadinostat) to standard chemotherapy can safely shrink pancreatic tumors that are borderline removable or locally advanced. About 30 adults with pancreatic cancer will receive the drug combination before surgery, then continue immunotherapy after. The main goal is to check for side effects, not yet to prove the treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nogapendekin alfa inbakicept (N-803), sotevtamab, zabadinostat, gemcitabine, nab-paclitaxel
What this could lead to
If this works, it could point toward a more effective treatment approach for pancreatic cancer that is hard to remove with surgery alone.
What could go wrong
This is a very early, small phase 1 trial focused on safety, not effectiveness. The drug combination may cause serious side effects and may not shrink tumors enough to allow surgery.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.